Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 14/20 | 0.79 |
| ▸ | PDE4A | P27815 | 5/20 | 0.58 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.58 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6688327 | 0.88 | TNF (1.00) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6689045 | 0.82 | ALDH1A1 (0.65) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6690018 | 0.82 | TNF (0.78) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL15663491 | 0.81 | TNF (0.64) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL23112417 | 0.79 | TNF (0.61) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3338144 | 0.79 | TNF (0.61) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL15664377 | 0.79 | TNF (0.61) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6690004 | 0.78 | TNF (1.00) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6691297 | 0.78 | TNF (1.00) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3121844 | 0.78 | TNF (1.00) | TNFPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1477486-A2 | Imides as inhibitors of TNF alpha | CELGENE CORPORATION (US) | 2004-11-17 | — | — | EP | disclosed |
| EP-0706521-B1 | IMIDES AS TNF ALPHA INHIBITORS | CELGENE CORP (US) | 2002-10-02 | — | — | EP | disclosed |
| US-6075041-A | TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 2000-06-13 | — | — | US | disclosed |
| EP-1004572-A2 | Amines as inhibitors of TNF alpha | CELGENE CORPORATION (US) | 2000-05-31 | — | — | EP | disclosed |
| EP-1004580-A2 | Imides as inhibitors of TNF alpha | CELGENE CORPORATION (US) | 2000-05-31 | — | — | EP | disclosed |
| EP-1004581-A2 | Process for the preparation of thalidomide | CELGENE CORPORATION (US) | 2000-05-31 | — | — | EP | disclosed |
| US-5877200-A | Cyclic amides | CELGENE CORPORATION (US) | 1999-03-02 | — | — | US | disclosed |
| US-5698579-A | INHIBITOR OF TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 1997-12-16 | — | — | US | disclosed |
| US-5605914-A | INHIBITORS OF TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 1997-02-25 | — | — | US | disclosed |